Apotex Targets Exclusivity Period In Generic Benicar Suit

Law360, New York (November 20, 2012, 7:43 PM EST) -- Apotex Inc. slapped Daiichi Sankyo Co. Ltd. with a patent suit in Illinois on Tuesday, seeking a noninfringement ruling which Apotex said could strip Mylan Laboratories Ltd. of exclusive rights to market a generic version of the hypertension drug Benicar.  

Matrix Laboratories Ltd., now Mylan Laboratories Ltd., was the first generic applicant to file a paragraph IV certification challenging U.S. Patent Numbers 5,616,599 and 6,878,703 with respect to 5-, 20- and 40-milligram olmesartan medoxomil — generic Benicar — tablets, the complaint said.

Daiichi sued Matrix but...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.